Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alphabet Inc Class A (GOOGL) vs Humana Inc (HUM) Price & Performance

Alphabet Inc Class ATrade
Humana IncTrade

Price performance (Past 24H)

Key statistics

Alphabet Inc Class A vs Humana Inc — how do they compare? Alphabet Inc Class A trades at $371.48 (market cap $4.52T), while Humana Inc trades at $394.29 (market cap $48.96B). The key difference: Alphabet Inc Class A is far larger — about 92.3× Humana Inc's market cap, and Humana Inc pays the higher dividend (0.87%). Which is the better fit depends on your goals.

GOOGLHUM
Market Cap
$4.52T$48.96B
Sector
MediaHealth
52-Week High
$402.62$409.42
52-Week Low
$182.97$163.67
Enterprise Value
$4.49T$58.00B
Dividend Yield
0.24%0.87%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alphabet Inc Class A

Alphabet (GOOGL) stock trades at $370.92, up 3.17% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $350B in 2024 to $402.8B in 2025 and net income surging 32% to $132.2B. Recent quarterly earnings consistently beat expectations, and the company initiated a dividend in 2026. Analyst sentiment remains overwhelmingly positive with 85% buy ratings and a $431.78 consensus price target, suggesting 16% upside potential.

The outlook for GOOGL appears favorable given strong AI-driven growth in cloud and advertising, expanding profitability margins, and solid cash flow generation. Key risks include regulatory scrutiny of antitrust practices, competitive pressures in AI and cloud services, and potential market volatility affecting tech valuations. The stock's current valuation at 28.29x P/E reflects premium pricing for its growth trajectory.

Humana Inc

Humana (HUM) trades at $406.70, up 0.17% on the day, and is currently above its consensus price target. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company has beaten earnings expectations for three consecutive quarters and is executing a strategic shift from membership growth to profitability, targeting a 3% Medicare Advantage margin by 2028. Revenue has grown consistently from $92.9B in 2022 to $129.7B in 2025.

The outlook is mixed. The company's strategic pivot and recent contract wins like the Illinois Medicaid contract present growth opportunities. However, significant risks include multiple legal investigations into statements on healthcare costs, declining net profit margins (from 3.02% in 2022 to 0.91% in 2025), and a high P/E ratio of 43.52. Analyst sentiment is cautious, with a majority 'Hold' rating and a consensus price target 13% below the current price.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alphabet Inc Class A

Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.

Read more on GOOGL

About Humana Inc

Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Read more on HUM